Neoadjuvant Immunotherapy in Gastroesophageal Cancer: A Promising Early Signal?
In the article that accompanies this editorial, Lorenzen et al 1 report exploratory efficacy findings, focused on pathologic response, of neoadjuvant immunotherapy–containing chemotherapy in patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma (GEA) in the ongoing DANTE/FLOT8 trial. DANTE is an open-label phase II/III trial (German AIO) in which patients are randomly assigned to receive pre-/post-operative FLOT with atezolizumab versus FLOT alone. To our knowledge, the current
